-
Late-breaking abstract at SUO: Novel oncolytic immunotherapy shows promise for patients with bladder cancer
Share this:
ROCHESTER, Minn. — A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of Urologic Oncology Annual Meeting in Dallas, Dec. 4-6.
The study demonstrated a potentially effective treatment for patients with bladder cancer who no longer respond to the common therapy, Bacillus Calmette-Guérin (BCG). The novel treatment, cretostimogene grenadenorepvec, is an oncolytic immunotherapy, meaning it is a virus designed to selectively replicate in and break down cancer cells while simultaneously amplifying the immune response against bladder tumors.
Efficacy data from 110 participants in the study showed that nearly 75% experienced complete cancer remission, with many remaining cancer-free beyond two years. Remarkably, most participants did not require bladder removal surgery, and the treatment was well tolerated with minimal serious side effects. Ongoing research will look to determine the long-term efficacy and whether combining this therapy with other treatments will enhance its effectiveness.
"These findings address a significant unmet need for bladder cancer patients and could improve their quality of life," says Mark Tyson, M.D., urologic oncologist and lead investigator of the study. "We now know this treatment can be both effective and safe, potentially reducing the need for bladder removal surgery and providing a much-needed alternative for patients with limited options."
The abstract, "Topline Results: BOND-003 cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ," will be presented by Dr. Tyson on Thursday, Dec. 5, 11:45–11:50 a.m. CST.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining the cancer center of the future, focused on delivering the world's most exceptional patient-centered cancer care for everyone. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs in cancer detection, prevention and treatment to change lives.
Media contact:
- Kelley Luckstein, Mayo Clinic Communications, newsbureau@mayo.edu
